Iridocorneal Angle and Anterior Segment Structure in Eyes of Children With Cataract (ACA)
Iridocorneal Angle and Anterior Segment Structure in Pediatric Cataract
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- children with cataract
Exclusion Criteria:
- a history of ocular trauma
- a history of intraocular surgery
- preoperative glaucoma
- steroid use before surgery
- a history of maternal rubella syndrome
- chronic anterior uveitis
- persistent fetal vasculature
- ocular anomalies associated with an increased risk of glaucoma
- unable to complete examinations.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
cataractous eyes
eyes of children with unilateral or bilateral cataract
|
gonioscopic observation and grading of iridocorneal angle
|
|
fellow eyes
fellow eyes of children with unilateral cataract
|
gonioscopic observation and grading of iridocorneal angle
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Width of angle
Time Frame: 2016-06-01 to 2018-06-01
|
The angle width was defined as follows: grade 0, a closed angle without visible angle structures; grade 1, a very narrow angle with Schwalbe's line visible only; grade 2, a moderately narrow angle with Schwalbe's line and trabecular meshwork visible; grade 3, an open angle with trabecular meshwork and scleral spur visible; grade 4, the widest angle with ciliary body band (CBB) visible
|
2016-06-01 to 2018-06-01
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Width of ciliary body band
Time Frame: 2016-06-01 to 2018-06-01
|
The width of ciliary body band(CBB) is defined as follows: invisible, the CBB could not be seen at all; very narrow, the CBB is narrower than the scleral spur; normal, the CBB is wider than the scleral spur
|
2016-06-01 to 2018-06-01
|
|
The number of iris processes
Time Frame: 2016-06-01 to 2018-06-01
|
The number of iris process is defined as follows: 0, none; 1, minimal; 2, moderate; 3, marked
|
2016-06-01 to 2018-06-01
|
|
Trabecular meshwork pigmentation
Time Frame: 2016-06-01 to 2018-06-01
|
The pigmentation of trabecular meshwork is defined as follows: 0, no pigment; 1, minimal pigment; 2, mild pigment
|
2016-06-01 to 2018-06-01
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ACA_LZL_HZ
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.